Regarding the ongoing Phase 1 study investigating the efficacy of OsteoDex in patients with progressive treatment-resistant multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The study is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology\/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed treatment-resistant disease, who received 1\u20135 prior lines of therapy. The primary objective is to confirm safety and tolerability and with a secondary objective to determine indications of treatment response. The number of patients to be included in the study will now be a maximum of 12 (previously a maximum of 20). Primary and secondary objectives can be achieved despite lower patient numbers and are an adaptation to available patients that can be recruited.
\nThrough reduced costs, the company can announce that operations are financed until Q4, 2026.<\/p>\n